JP2022547298A5 - - Google Patents

Info

Publication number
JP2022547298A5
JP2022547298A5 JP2022515475A JP2022515475A JP2022547298A5 JP 2022547298 A5 JP2022547298 A5 JP 2022547298A5 JP 2022515475 A JP2022515475 A JP 2022515475A JP 2022515475 A JP2022515475 A JP 2022515475A JP 2022547298 A5 JP2022547298 A5 JP 2022547298A5
Authority
JP
Japan
Prior art keywords
protein
composition
kit
hcmv
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022515475A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547298A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/075002 external-priority patent/WO2021048081A1/en
Publication of JP2022547298A publication Critical patent/JP2022547298A/ja
Publication of JP2022547298A5 publication Critical patent/JP2022547298A5/ja
Pending legal-status Critical Current

Links

JP2022515475A 2019-09-09 2020-09-08 免疫療法組成物 Pending JP2022547298A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962897603P 2019-09-09 2019-09-09
US62/897,603 2019-09-09
PCT/EP2020/075002 WO2021048081A1 (en) 2019-09-09 2020-09-08 Immunotherapeutic compositions

Publications (2)

Publication Number Publication Date
JP2022547298A JP2022547298A (ja) 2022-11-11
JP2022547298A5 true JP2022547298A5 (https=) 2023-09-15

Family

ID=72603444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515475A Pending JP2022547298A (ja) 2019-09-09 2020-09-08 免疫療法組成物

Country Status (9)

Country Link
US (2) US20210069321A1 (https=)
EP (1) EP4028051A1 (https=)
JP (1) JP2022547298A (https=)
CN (1) CN114466659A (https=)
BR (1) BR112022004228A2 (https=)
CA (1) CA3092525A1 (https=)
IL (1) IL290854A (https=)
MX (1) MX2022002823A (https=)
WO (1) WO2021048081A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019025104A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição
EP3886901A1 (en) * 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
BR112021024157A2 (pt) * 2019-05-31 2022-04-26 Variation Biotechnologies Inc Composições imunoterapêuticas para tratamento de glioblastoma multiforme
EP4021407A1 (en) 2019-08-30 2022-07-06 GlaxoSmithKline Biologicals S.A. Jet mixing lipid nanoparticle manufacturing process
WO2023020994A1 (en) * 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
EP4654998A2 (en) * 2023-01-26 2025-12-03 The General Hospital Corporation T cell-directed anti-aging and anti-cancer vaccines against commensal cytomegalovirus
WO2025179112A1 (en) * 2024-02-23 2025-08-28 Curevo, Inc. Immunogenic compositions for the prevention of herpes zoster
TW202600165A (zh) * 2024-02-29 2026-01-01 優億股份有限公司 佐劑組合物、包含該佐劑組合物的藥物組合物以及預防或治療病毒感染、細菌感染、原蟲感染或癌症引起的疾病的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
EP0362278A4 (en) 1987-06-05 1990-05-14 Us Health Autocrine motility factors in cancer diagnosis and management.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
CA2252972C (en) 1998-11-26 2012-09-18 National Research Council Of Canada Serum-free production of recombinant proteins and adenoviral vectors
US6210922B1 (en) 1998-11-30 2001-04-03 National Research Council Of Canada Serum free production of recombinant proteins and adenoviral vectors
HU230847B1 (en) 2000-05-19 2018-08-28 Corixa Corp Prophylactic and therapeutic treatment of infectious and other diseases with mono and disaccharide-based compounds
CA2417806C (en) 2000-08-04 2011-05-10 Corixa Corporation New immunoeffector compounds
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US7288640B2 (en) 2002-07-08 2007-10-30 Corixa Corporation Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2068918T5 (pl) 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
PL2137210T3 (pl) * 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
EP3156069B8 (en) * 2008-06-20 2020-10-21 Duke University Compositions, methods, and kits for eliciting an immune response
CN106822883A (zh) 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
CA2889659C (en) 2011-11-11 2023-03-14 Variation Biotechnologies Inc. Compositions and methods for treatment of cytomegalovirus
US11220630B2 (en) 2016-12-23 2022-01-11 Qustomdot B.V. Quantum dots with a III-V core and an alloyed II-VI external shell

Similar Documents

Publication Publication Date Title
JP2022547298A5 (https=)
JP7785817B2 (ja) がんに対する組合せ療法
Chikh et al. Liposomal delivery of CTL epitopes to dendritic cells
JP6945301B2 (ja) Ｈｐｖおよび関連する疾病のための免疫増強治療ワクチン
Gerard et al. Therapeutic potential of protein and adjuvant vaccinations on tumour growth
Si et al. The safety and immunological effects of rAd5-EBV-LMP2 vaccine in nasopharyngeal carcinoma patients: a phase I clinical trial and two-year follow-up
EP2155780B1 (en) P53 peptide vaccine
JP2023513720A5 (https=)
EP3269387B1 (en) Polynucleotides and polypeptides for treating oncogenic viral polypeptide positive tumors
EP1925317A1 (de) Stabilisierte mRNA Tumorvakzine
JP2002508333A (ja) ワクチン
JP2014506562A5 (ja) 治療的免疫応答及び予防的免疫応答の両方を誘発するポリペプチド（複数可）保持ＣｙａＡ及びその使用
WO2021228106A1 (zh) 溶瘤病毒与免疫检查点抑制剂联合治疗肿瘤
Yang et al. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo
Wang et al. Immune responses to varicella-zoster virus glycoprotein E formulated with poly (lactic-co-glycolic acid) nanoparticles and nucleic acid adjuvants in mice
JP2001516727A (ja) 新生物または癌性増殖の治療用もしくは造血の修復または作用促進用の相乗組成物および方法
JP2021506767A (ja) Ｂ型肝炎免疫化レジメン及び組成物
KR101361769B1 (ko) Ｈｐｖ-16 ｌ1 ｖｌｐ 및 ｈｐｖ-18 ｌ1 ｖｌｐ 백신
JP2018500322A5 (https=)
Torréns et al. Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors
KR102728174B1 (ko) 백신 보조제로서 gm3 강글리오시드의 합성 변이체를 포함하는 나노입자
CN119770632A (zh) 诱导免疫应答的组合物和方法
CN114409744B (zh) Hpv抗原表位及其鉴定方法、应用
JP2021506771A (ja) Ｂ型肝炎免疫化レジメン及び組成物
WO2004052395A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles